Fox E, et al. Final results of a placebo controlled, Phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS). ECTRIMS 2018, abstract 229.
ECTRIMS 2015 video update Teunissen: Will MS be prevented?
jun 2017